Stockscreener 앱 받기
0.79
3.08%
-0.0251
시장 영업 전:
.81
0.02
+2.53%
Ocugen Inc 주식(OCGN)의 최신 뉴스
Ocugen (NasdaqCM:OCGN) Stock Forecast & Analyst Predictions - Simply Wall Street
An officer proposes selling 525,991 Ocugen (OCGN) shares through Merrill Lynch. - Stock Titan
Ocugen Stockholders Approve Meeting Adjournment for Share Increase - The Globe and Mail
Ocugen CEO Musunuri sells $589,109 in shares, priced $1.06-$1.31 By Investing.com - Investing.com Australia
Ocugen CEO Musunuri sells $589,109 in shares, priced $1.06-$1.31 By Investing.com - Investing.com Canada
Ocugen CEO Musunuri sells $589,109 in shares, priced $1.06-$1.31 - investing.com
Ocugen: Q3 Data Catalyst In Stargardt Disease Feels Critical (NASDAQ:OCGN) - Seeking Alpha
Analysts Offer Insights on Healthcare Companies: Zymeworks (ZYME), Axsome Therapeutics (AXSM) and Ocugen (OCGN) - The Globe and Mail
Ocugen CEO Musunuri sells $589,109 in shares, priced $1.06-$1.31 - Investing.com
Ocugen Inc. stock falls Thursday, underperforms market - MarketWatch
OCGN Stock Slips As Traders Focus On Weak Financials - StocksToTrade
OCGN Stock Slips As Weak Financials Weigh On Momentum - timothysykes.com
Ocugen: My Hold Rating Continued On OCU410ST Advancement And Upcoming Catalysts (OCGN) - Seeking Alpha
What's Happening With Ocugen Stock Thursday? - TradingView
H.C. Wainwright cuts Ocugen stock price target to $9.50 on trial delay - Investing.com India
H.C. Wainwright cuts Ocugen stock price target to $9.50 on trial delay - Investing.com Canada
H.C. Wainwright cuts Ocugen stock price target to $9.50 on trial delay - Investing.com UK
H.C. Wainwright cuts Ocugen stock price target to $9.50 on trial delay - Investing.com
OCGN Maintains Buy by HC Wainwright & Co. -- Price Target Lowered to $9.50 - GuruFocus
H.C. Wainwright cuts Ocugen stock price target to $9.50 on trial delay By Investing.com - Investing.com South Africa
Ocugen Inc. stock falls Wednesday, underperforms market - MarketWatch
An Ocugen (NASDAQ: OCGN) insider plans a stock sale; the exact size is detailed in an SEC notice - Stock Titan
OCGN Looks 32.9% Overvalued on GF Value™ Amid Phase 2/3 Trial Se - GuruFocus
Ocugen slips after Stargardt disease trial data (OCGN:NASDAQ) - Seeking Alpha
OCGN Stock Slides As Traders Focus On Cash Burn And Key Support - timothysykes.com
Ocugen doses first patient in phase 3 GA gene therapy trial - Glance by Eyes On Eyecare
Ocugen Announces US$40 Million Registered Direct Offering Priced at $2.00 Per Share - Minichart
Ocugen to Share Ophthalmic Gene Therapy Progress - TipRanks
Ocugen Inc. stock falls Tuesday, underperforms market - MarketWatch
Ocugen Doses First Patient in Phase 3 Trial of OCU410 for GA - cgtlive.com
Malvern’s Ocugen Starts Pivotal Trial for Eye Gene Therapy - MyChesCo
Ocugen stock edges higher as investors watch recent quarterly figures - AD HOC NEWS
Ocugen Inc. stock rises Thursday, outperforms market - MarketWatch
Ocugen (NASDAQ:OCGN) Penny Stock Nears Major Gene Therapy Catalyst - Kalkine Media
OCGN Advances Gene Therapy OCU410 In Phase III for Geographic Atrophy - Yahoo Finance
Ocugen Doses First Patient in Global Phase 3 Trial of OCU410 for Geographic Atrophy - Eyewire+
Ocugen Eases on Tests - Baystreet.ca
Ocugen doses first patient in phase 3 gene therapy trial for GA - Investing.com Canada
OCGN Looks 61.0% Overvalued on GF Value™ - GuruFocus
Ocugen doses first patient in phase 3 gene therapy trial for GA - Investing.com Australia
Ocugen doses first patient in phase 3 gene therapy trial for GA - Investing.com Nigeria
Ocugen doses first patient in phase 3 gene therapy trial for GA - Investing.com
Ocugen Doses First Patient in Global Phase 3 ArMaDa3 Trial of OCU410 for Geographic Atrophy and Receives FDA RMAT Designation - Quiver Quantitative
Ocugen doses first patient in phase 3 gene therapy trial for GA - Investing.com UK
Ocugen Announces First Patient Dosed in Phase 3 Registrational Trial of OCU410 Modifier Gene Therapy for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration - Ocugen, Inc.
Ocugen Doses First Patient in OCU410 Phase 3 Trial | OCGN Stock News - Stock Titan
Ocugen Announces First Patient Dosed in Phase 3 Registrational Trial of OCU410 Modifier Gene Therapy for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration - Yahoo Finance
Ocugen Eases on Tests - Baystreet.ca
Malvern Biotech Ocugen to Present New Eye Gene Therapy Data - MyChesCo
Ocugen Inc. stock falls Friday, underperforms market - MarketWatch
0.68%
3.98%
자본화:
|
볼륨(24시간):